CA
NZ
UK
AU
IND
US
Pyxis Oncology, Inc. (NASDAQ: PYXS) reported updated Phase 1 results for MICVO that support advancing the drug into a key program after a 36% confirmed objective response rate, or 12 of 33 efficacy-evaluable patients. The study evaluated patients with second-line and beyond recurrent or …
QIAGEN N.V. (NYSE: QGEN) appointed Jonathan M. Pratt as chief executive officer effective September 1, 2026, succeeding Thierry Bernard. Bernard also stepped down from the Managing Board on that date, while QIAGEN reaffirmed its third-quarter and full-year 2026 outlook.
RAD301 Shows Selective Pancreatic Tumor Uptake
Satellos Bioscience Inc. (NASDAQ: MSLE) will use forazapadin as the international nonproprietary name for its lead drug candidate, previously known as SAT-3247. The orally administered small molecule is being evaluated in clinical studies for Duchenne muscular dystrophy, while Satellos intends to begin a trial …
SERA PROGNOSTICS, INC. (NASDAQ: SERA) shares held by Chief Executive Officer Lindgardt Zhenya fell by 20,139 at a transaction price of $2 per share. The sale took place on September 8, 2026. The reported sale price was $2 per share.
Serina Therapeutics, Inc. (AMEX: SER) is advancing SER-252 into the next cohort of its ongoing Phase 1b study in patients with advanced Parkinson’s disease.
Opaleye Management Inc. a 10% owner of Sol-Gel Technologies Ltd. (NASDAQ: SLGL), purchased 9,976 shares across five transactions between 4 September 2026 and 9 September 2026. The purchases carried SEC transaction code P.
Teleflex Inc (NYSE: TFX) appointed Sean M. Salmon to its board on September 8, 2026, adding medical-technologyLeadershiptied to a former Medtronic cardiovascularBusinesswith approximately $12.5 billion in fiscal 2025 revenue. Salmon also joined Teleflex’s Growth and Operating Committee.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) will consolidate every 20 ordinary shares into one under a 1-for-20 reverse split. The transaction will reduce issued and outstanding ordinary shares from 37,938,036 to 1,896,902, subject to any further adjustment arising from fractional-share treatment.
NovoCure Ltd (NASDAQ: NVCR) lost Timothy Scannell from its Board effective September 2, 2026, when his seat was vacated under the company’s Articles of Association. The retirement was not attributed to any disagreement with NovoCure or its management.
Please wait processing your request...